Adam Jorgensen, MD
Glaucoma Specialist · Rapid City, SDNPI 1366700460
Payments from drug & device makers
Across 226 payments — averaging $1116.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$154K
- AbbVie$92K
- NEW World Medical,inc.$3K
- US Retina LLC$3K
- Alcon$218
- Ivantis, Inc$168
- plus $350 from 7 others
Across 19 payments — averaging $1500.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$29K
What the payments were for
- Consulting fees$1503%
- Travel & lodging$180%
- Food & beverage$2,04142%
- Gifts$451%
- Ownership interest$2,63154%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 124 | $153,941 |
| AbbVie(2 entities) | 49 | $92,142 |
| NEW World Medical,inc. | 16 | $2,905 |
| US Retina LLC | 12 | $2,631 |
| Alcon | 8 | $218 |
| Ivantis, Inc | 2 | $168 |
| Biotissue Holdings Inc. | 1 | $95 |
| Sight Sciences, Inc. | 1 | $71 |
| Aerie Pharmaceuticals, Inc. | 5 | $68 |
| Omeros Corporation | 5 | $65 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $13 |
| Rayner Intraocular Lenses Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus$150
How this compares
Too few glaucoma specialist providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 154 | $65,359 |
| LumiganBimatoprost | 124 | $54,917 |
| CombiganBrimonidine Tartrate/Timolol | 126 | $34,909 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $30,133 |
| Latanoprost | 1,384 | $11,273 |
| Prednisolone Acetate | 373 | $10,822 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 66 | $10,416 |
| RestasisCyclosporine | 13 | $8,972 |
| Brimonidine Tartrate | 370 | $8,553 |
| Travoprost | 50 | $7,373 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 363 | $6,604 |
| Ketorolac Tromethamine | 367 | $6,443 |
| Alphagan PBrimonidine Tartrate | 20 | $5,981 |
| Timolol Maleate | 546 | $5,403 |
| Ofloxacin | 285 | $3,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $92,142 | $104,779283 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $68 | $95,492221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.